Drystone LLC Invests $2.06 Million in Kenvue Inc. (NYSE:KVUE)

Drystone LLC bought a new position in Kenvue Inc. (NYSE:KVUE) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 96,590 shares of the company’s stock, valued at approximately $2,062,000. Kenvue makes up 2.1% of Drystone LLC’s portfolio, making the stock its 15th biggest holding.

A number of other large investors have also bought and sold shares of the business. Leo Wealth LLC lifted its position in shares of Kenvue by 0.3% during the third quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock worth $3,507,000 after purchasing an additional 481 shares in the last quarter. Alerus Financial NA raised its position in Kenvue by 0.3% in the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock worth $4,426,000 after purchasing an additional 491 shares during the last quarter. Massmutual Trust Co. FSB ADV lifted its holdings in Kenvue by 6.2% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock worth $194,000 after buying an additional 492 shares in the last quarter. Kiley Juergens Wealth Management LLC boosted its position in Kenvue by 1.9% in the 4th quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock valued at $579,000 after buying an additional 500 shares during the last quarter. Finally, Wolff Wiese Magana LLC increased its stake in shares of Kenvue by 0.7% in the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock valued at $1,781,000 after buying an additional 501 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Kenvue Price Performance

KVUE opened at $21.35 on Thursday. The stock has a market cap of $40.92 billion, a P/E ratio of 38.81, a P/E/G ratio of 1.99 and a beta of 1.46. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The company has a fifty day simple moving average of $22.05 and a 200 day simple moving average of $21.85.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. The company had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company’s revenue for the quarter was down .4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.31 earnings per share. On average, research analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.84%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s payout ratio is currently 149.09%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Barclays cut their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. Royal Bank of Canada upgraded shares of Kenvue from a “hold” rating to a “moderate buy” rating in a research report on Monday, December 9th. Bank of America lifted their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and cut their price objective for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Finally, Citigroup lowered their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Kenvue has a consensus rating of “Hold” and an average price target of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.